AAAAAA

   
Results: 1-10 |
Results: 10
PLEASE DONT HIJACK QUALITY-OF-LIFE - REPLY
Authors: SANTANELLO NC POLIS AB HARTMAIER SL KRAMER MS BLOCK GA SILBERSTEIN SD
Citation: Nc. Santanello et al., PLEASE DONT HIJACK QUALITY-OF-LIFE - REPLY, Cephalalgia, 18(4), 1998, pp. 227-228
ASSOCIATION OF SERUM PHOSPHORUS AND CALCIUM X PHOSPHATE PRODUCT WITH MORTALITY RISK IN CHRONIC-HEMODIALYSIS PATIENTS - A NATIONAL STUDY
Authors: BLOCK GA HULBERTSHEARON TE LEVIN NW PORT FK
Citation: Ga. Block et al., ASSOCIATION OF SERUM PHOSPHORUS AND CALCIUM X PHOSPHATE PRODUCT WITH MORTALITY RISK IN CHRONIC-HEMODIALYSIS PATIENTS - A NATIONAL STUDY, American journal of kidney diseases, 31(4), 1998, pp. 607-617
THE SUBSTANCE-P RECEPTOR ANTAGONIST L-754,030 (MK-0869) IS INEFFECTIVE IN THE TREATMENT OF POSTHERPETIC NEURALGIA
Authors: BLOCK GA RUE D PANEBIANCO D REINES SA
Citation: Ga. Block et al., THE SUBSTANCE-P RECEPTOR ANTAGONIST L-754,030 (MK-0869) IS INEFFECTIVE IN THE TREATMENT OF POSTHERPETIC NEURALGIA, Neurology, 50(4), 1998, pp. 4084-4084
2-PERIOD CROSSOVER COMPARISON OF RIZATRIPTAN 5 MG AND 10 MG TO SUMATRIPTAN 25 MG AND 50 MG FOR THE ACUTE TREATMENT OF MIGRAINE
Authors: NORMAN BA BLOCK GA JIANG K AHRENS S
Citation: Ba. Norman et al., 2-PERIOD CROSSOVER COMPARISON OF RIZATRIPTAN 5 MG AND 10 MG TO SUMATRIPTAN 25 MG AND 50 MG FOR THE ACUTE TREATMENT OF MIGRAINE, Neurology, 50(4), 1998, pp. 46005-46005
RESPONSE OF A 24-H MIGRAINE QUALITY-OF-LIFE QUESTIONNAIRE IN A CLINICAL-TRIAL
Authors: SANTANELLO NC POLIS AB HARTMAIER SL BLOCK GA SILBERSTEIN SD
Citation: Nc. Santanello et al., RESPONSE OF A 24-H MIGRAINE QUALITY-OF-LIFE QUESTIONNAIRE IN A CLINICAL-TRIAL, Quality of life research, 6(5), 1997, pp. 74-74
IMPROVEMENT IN MIGRAINE-SPECIFIC QUALITY-OF-LIFE IN A CLINICAL-TRIAL OF RIZATRIPTAN
Authors: SANTANELLO NC POLIS AB HARTMAIER SL KRAMER MS BLOCK GA SILBERSTEIN SD
Citation: Nc. Santanello et al., IMPROVEMENT IN MIGRAINE-SPECIFIC QUALITY-OF-LIFE IN A CLINICAL-TRIAL OF RIZATRIPTAN, Cephalalgia, 17(8), 1997, pp. 867-872
RIZATRIPTAN (MK-0462) FOR THE ACUTE TREATMENT OF MIGRAINE AND MIGRAINE RECURRENCE
Authors: BLOCK GA SMITH M JIANG K REINES S TEALL J
Citation: Ga. Block et al., RIZATRIPTAN (MK-0462) FOR THE ACUTE TREATMENT OF MIGRAINE AND MIGRAINE RECURRENCE, Neurology, 48(3), 1997, pp. 1135-1135
FINAL RESULTS FROM A DOSE-ESCALATING SAFETY AND TOLERANCE STUDY OF THE NONCOMPETITIVE NMDA ANTAGONIST CNS1102 IN PATIENTS WITH ACUTE CEREBRAL-ISCHEMIA
Authors: BLOCK GA
Citation: Ga. Block, FINAL RESULTS FROM A DOSE-ESCALATING SAFETY AND TOLERANCE STUDY OF THE NONCOMPETITIVE NMDA ANTAGONIST CNS1102 IN PATIENTS WITH ACUTE CEREBRAL-ISCHEMIA, Stroke, 26(1), 1995, pp. 185-185
CONTROLLED-RELEASE LEVODOPA CARBIDOPA-25/100 (SINEMET CR-25/100) - PHARMACOKINETICS AND CLINICAL EFFICACY IN UNTREATED PARKINSONIAN-PATIENTS/
Authors: HAMMERSTAD JP WOODWARD WR NUTT JG GANCHER ST BLOCK GA CYHAN G
Citation: Jp. Hammerstad et al., CONTROLLED-RELEASE LEVODOPA CARBIDOPA-25/100 (SINEMET CR-25/100) - PHARMACOKINETICS AND CLINICAL EFFICACY IN UNTREATED PARKINSONIAN-PATIENTS/, Clinical neuropharmacology, 17(5), 1994, pp. 429-434
A MULTIPLE-DOSE SAFETY TRIAL OF EPTASTIGMINE IN ALZHEIMERS-DISEASE, WITH PHARMACODYNAMIC OBSERVATIONS OF RED-BLOOD-CELL CHOLINESTERASE
Authors: SRAMEK JJ BLOCK GA REINES SA SAWIN SF BARCHOWSKY A CUTLER NR
Citation: Jj. Sramek et al., A MULTIPLE-DOSE SAFETY TRIAL OF EPTASTIGMINE IN ALZHEIMERS-DISEASE, WITH PHARMACODYNAMIC OBSERVATIONS OF RED-BLOOD-CELL CHOLINESTERASE, Life sciences, 56(5), 1994, pp. 319-326
Risultati: 1-10 |